- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2014
- Public Summary Document (PSD) November 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2014 PBAC Meeting - Word
Dolutegravir + abacavir + lamivudine – November 2014
Dolutegravir + abacavir + lamivudine; dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg tablet, 30; Triumeq®
Last updated
6 March 2015